GlaxoSmithKline Stock Rating Reaffirmed by BNP Paribas (GSK)
GlaxoSmithKline (LON:GSK)‘s stock had its “underperform” rating reaffirmed by BNP Paribas in a research note issued on Thursday, Stock Ratings Network reports. They currently have a GBX 1,600 ($26.29) target price on the stock. BNP Paribas’ target price points to a potential upside of 0.13% from the stock’s previous close.
GSK has been the subject of a number of other recent research reports. Analysts at Deutsche Bank cut their price target on shares of GlaxoSmithKline from GBX 1,700 ($27.94) to GBX 1,620 ($26.62) in a research note to investors on Thursday. They now have a “hold” rating on the stock. Separately, analysts at Societe Generale cut their price target on shares of GlaxoSmithKline from GBX 1,960 ($32.21) to GBX 1,950 ($32.05) in a research note to investors on Monday. They now have a “buy” rating on the stock. Finally, analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Friday, January 31st. They now have a GBX 1,600 ($26.29) price target on the stock. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company’s stock. GlaxoSmithKline currently has a consensus rating of “Hold” and an average target price of GBX 1,718.82 ($28.25).
GlaxoSmithKline (LON:GSK) traded up 1.17% on Thursday, hitting GBX 1598.00. 9,059,549 shares of the company’s stock traded hands. GlaxoSmithKline has a 52 week low of GBX 1430.00 and a 52 week high of GBX 1816.00. The stock’s 50-day moving average is GBX 1602. and its 200-day moving average is GBX 1618.93. The company’s market cap is £76.976 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.